PharmaNutrition最新文献

{"title":"Vitamin D does not mitigate monocyte adhesion to vascular endothelial cells in an in vitro pro-inflammatory model","authors":"Mirko Marino ,&nbsp;Samuele Venturi ,&nbsp;Peter Møller ,&nbsp;Marco Rendine ,&nbsp;Daniela Martini ,&nbsp;Patrizia Riso ,&nbsp;Cristian Del Bo'","doi":"10.1016/j.phanu.2025.100454","DOIUrl":"10.1016/j.phanu.2025.100454","url":null,"abstract":"<div><div>Vitamin D deficiency has been associated with cardiovascular risk factors, including endothelial dysfunction, a critical step in the pathogenesis of atherosclerosis. This study aimed to evaluate the effects of 1α,25-dihydroxycholecalciferol (VD3) on monocyte (THP-1) adhesion to human umbilical vein endothelial cells (HUVECs) under a pro-inflammatory condition. Endothelial cell activation was induced with tumor necrosis factor-alpha (TNF-α, 100 ng/mL), and cells were treated with VD3 at concentrations ranging from 0.1 to 100 nM. Monocyte adhesion was quantified spectrophotometrically, while levels of vascular cell adhesion molecule 1 (VCAM-1), E-selectin, and cluster of differentiation 15 (CD15) were assessed using ELISA. TNF-α significantly increased THP-1 cell adhesion to HUVECs compared to the control group (p &lt; 0.05). Co-treatment with VD3 at all concentrations tested did not reduce monocyte adhesion, showing levels similar to the TNF-α only group, and significantly higher than the negative control (p &lt; 0.05). Furthermore, TNF-α significantly upregulated VCAM-1 expression (p &lt; 0.05), which was unaffected by VD3. E-selectin and CD15 levels remained unchanged under all experimental conditions. These results do not support a modulatory role for VD3 in the early stages of atherogenesis, specifically in reducing endothelial cell activation and monocyte adhesion. While vitamin D has shown beneficial effects in other aspects of cardiovascular health, its impact on vascular inflammation and adhesion processes remains uncertain and needs further investigation.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"34 ","pages":"Article 100454"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145183786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nicotinamide improves physiological outcomes in an arginine vasopressin rat model of pre-eclampsia","authors":"Rebecca Reddy ,&nbsp;Sooraj Baijnath ,&nbsp;Nalini Govender","doi":"10.1016/j.phanu.2025.100459","DOIUrl":"10.1016/j.phanu.2025.100459","url":null,"abstract":"<div><div>Pre-eclampsia (PE) is a hypertensive disorder of pregnancy that poses a substantial risk to both maternal and fetal health, especially in low-middle-income countries. Despite advancements in pregnancy-related research, effective treatment options for PE remain limited, emphasizing the need for innovative therapeutic strategies in regions that are under-resourced with the highest burden. In this light, there has been growing interest in the safety and efficacy of natural products, where nicotinamide (NAM) has emerged as a promising candidate for alternative PE management. This study aims to evaluate the therapeutic potential of NAM in a preclinical model of PE, specifically assessing its effects on blood pressure, placental and fetal development, and hematological parameters. Twenty-four pregnant female Sprague Dawley rats were subcutaneously administered arginine vasopressin (AVP) via mini osmotic pumps (infused at a rate of 200 ng/h). AVP-administered rodents received either NAM (p.o., 200 mg/kg body weight) or captopril (p.o., 40 mg/kg body weight (BW)) for two weeks. Our findings demonstrate that NAM effectively reduced both systolic and diastolic blood pressure in AVP-treated rats, reduced urinary protein levels and the urine protein-to-creatinine ratio (UPCR), alongside improvements in hematological parameters. Concerning pregnancy outcomes, NAM administrations significantly increased urine output and placental and individual pup weights. These findings highlight the preclinical efficacy of NAM in ameliorating the symptoms associated with hypertension in pregnancy, improving both maternal and fetal well-being, and paving the way for future research into the use of NAM.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"34 ","pages":"Article 100459"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145418244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic advances in hyperuricemia and anti-hyperuricemia therapies","authors":"Mingyue Ao ,&nbsp;Xi Zhang ,&nbsp;Ru Chen ,&nbsp;Chun Xiao ,&nbsp;Yinhua Liu ,&nbsp;Min Gao ,&nbsp;Ya Zhang","doi":"10.1016/j.phanu.2025.100456","DOIUrl":"10.1016/j.phanu.2025.100456","url":null,"abstract":"<div><div>Hyperuricemia (HUA) is a systemic metabolic disorder characterized by disturbances in uric acid metabolism and elevated serum uric acid levels, and it is a major risk factor for gout. It has risen to become the second largest metabolic disease threatening human health, and is known as one of the \"four highs\" along with hypertension, hyperlipidemia, and hyperglycemia. At present, clinical treatment for HUA can be divided into three categories: inhibiting uric acid production, promoting uric acid excretion, and decomposing uric acid. Although the mechanism is clear and the effect is significant, there are varying degrees of safety risks involved. Therefore, a growing number of studies are dedicated to finding new pathogenic mechanisms or potential therapeutic targets for HUA. It is of great significance to comprehensively understand HUA and develop feasible and effective treatment methods. In this review, we systematically elucidate the pathogenesis, related drug treatment progress, and strategies for regulating HUA by gut microbiota. At the same time, the effects of different dietary structures on gut microbiota and the impact of gut microbiota on purine and uric acid metabolism were explored. In addition, the intervention effects of probiotics and prebiotics on HUA were systematically evaluated, in order to provide theoretical basis for the research and development of uric acid lowering drugs.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"34 ","pages":"Article 100456"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145418243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The healing power of Manuka honey: A comprehensive review of its anti-cancer properties","authors":"Idrisa Kiryowa ,&nbsp;Aya Darwish ,&nbsp;Denis Baranenko ,&nbsp;Tamer M. El-Messery ,&nbsp;Mohamed Said Boulkrane","doi":"10.1016/j.phanu.2025.100462","DOIUrl":"10.1016/j.phanu.2025.100462","url":null,"abstract":"<div><div>Leptospermum scoparium, or Manuka honey, contains active elements such as methylglyoxal, methylsyringate, and leptosin that have been identified to possess anti-cancer property. These molecules eradicate cancer cells by a reduction of the AKT/mTOR pathway, the damping of the stress caused by oxidation, and the induction of apoptosis. Studies on animals have proved that those substances have capacities to inhibit the growth of tumors in breast, colorectal, and liver cancers, both in vitro and in vivo. Manuka honey not only protects the body from side effects of chemotherapeutics but also increases the efficiency of the drugs. The usage of this method in clinical practice still holds back due to the bioavailability, variations in the compounds, and the standardization of the dose. Manuka honey has become a potential adjunct therapy that not only enhances the treatment outcomes but also maintains the minimal side effects. This meta-analysis paper pinpoints not only limited potential but, in fact, multi-targeted therapeutic ability the honey possesses. However, despite the growing evidence supporting its biological activity, there are still several challenges to be addressed before its clinical application. These include issues related to bioavailability, standardization of formulations based on UMF classification, and the lack of well-controlled human clinical trials. Additionally, future research should focus on developing advanced delivery systems, such as nanoparticle formulations, to enhance the stability and targeted delivery of the bioactive components in manuka honey. In conclusion, manuka honey holds great promise as a complementary therapy in oncology. With its multi-target mechanisms and robust safety profile, it offers a valuable opportunity for incorporation into cancer treatment protocols. Addressing current application barriers will be essential to fully realize its therapeutic potential in clinical settings.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"34 ","pages":"Article 100462"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the potential of Tropaeolum majus, a non-conventional food plant, in lipid and glucose metabolism","authors":"Mariana Buranelo Egea ,&nbsp;Ailton Cesar Lemes","doi":"10.1016/j.phanu.2025.100455","DOIUrl":"10.1016/j.phanu.2025.100455","url":null,"abstract":"<div><div>Brazil has one of the world's richest plant biodiversity, with approximately 46,000 species, including approximately 3000 non-conventional food plants (NCFPs). However, the nutritional, bioactive, and technological potentials of these plants remain underutilized and often overlooked. <em>Tropaeolum majus</em> (<em>T. majus</em>), an underexplored NCFPs, has shown promise in modulating lipid and glucose metabolism, which are key factors in metabolic health. Metabolic potential is closely linked to diverse bioactive compounds, including flavonoids, glucosinolates, and antioxidants, which contribute to its health-promoting properties. Moreover, it is a edible plant with a complete nutritional composition, characterized by high levels of protein and fiber along with low lipid content, making it an appealing option for both dietary inclusion and as a raw material for extracting and isolating valuable components. This review aimed to present information about the production processes, physicochemical characteristics, and bioactive potential of <em>T. majus</em>, emphasizing its role as a regulator of lipid and glucose metabolism, as supported by current scientific evidence.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"34 ","pages":"Article 100455"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145418242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peiminine as an anti-inflammatory agent: Mechanisms and therapeutic applications across diseases","authors":"Amin Azizan ,&nbsp;Mohamadali Abyazi ,&nbsp;Seyed Kiarash Aghayan ,&nbsp;Majid Mirzaei Nodooshan ,&nbsp;Akbar Ghorbani Alvanegh ,&nbsp;Hadi Esmaeili Gouvarchin Ghaleh","doi":"10.1016/j.phanu.2025.100460","DOIUrl":"10.1016/j.phanu.2025.100460","url":null,"abstract":"<div><div>Inflammatory diseases, including cancers and autoimmune disorders, demand therapeutic strategies that are both effective and associated with fewer side effects. Current treatment modalities, particularly immunosuppressive agents, often exhibit limited efficacy and undesirable outcomes, necessitating exploration into alternative solutions. Natural compounds have emerged as promising candidates for addressing this gap. This review focuses on peiminine, a bioactive alkaloid derived from the Fritillaria species, investigating its potential as a natural therapeutic agent. A comprehensive search was conducted across multiple databases, including MEDLINE, EMBASE, and Scopus, to collate evidence from preclinical studies assessing the anti-inflammatory and disease-modulating properties of peiminine. The findings reveal that peiminine exhibits significant potential in ameliorating a range of conditions, such as cancers, autoimmune diseases, and other inflammation-driven disorders like endometriosis and Parkinson's disease in preclinical stages. Mechanistically, peiminine exerts its effects by inhibiting critical signaling pathways, including NF-κB and ERK, and by regulating cell cycle progression and apoptosis. The preclinical literature highlights its promise as a natural therapeutic agent for future studies such as clinical trials. Harnessing the therapeutic potential of peiminine could pave the way for more effective and safer treatment strategies for inflammatory diseases.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"34 ","pages":"Article 100460"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145474414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential strategies of natural products in the treatment of atherosclerosis: Focusing on modulating macrophage polarization","authors":"Wenjie Zhao ,&nbsp;Peng Sun ,&nbsp;Jiaming Huan ,&nbsp;Lei Zhang ,&nbsp;Shijing Peng ,&nbsp;Tong Jiang ,&nbsp;Linghui Kong ,&nbsp;Xinghao Zhu ,&nbsp;Wenqing Yang ,&nbsp;Dongmei Qi ,&nbsp;Yunlun Li","doi":"10.1016/j.phanu.2025.100461","DOIUrl":"10.1016/j.phanu.2025.100461","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerosis is the primary contributor to coronary artery disease, peripheral artery disease, and cerebrovascular disease, making it one of the most prevalent causes of mortality worldwide. Macrophages play crucial roles in all stages of atherosclerosis development, providing new avenues for therapeutic interventions due to their inherent plasticity. Consequently, therapies aimed at macrophages may be advantageous for both the prevention and treatment of atherosclerosis. Accumulating evidence strongly indicates that traditional Chinese medicine (TCM) and its derived natural products have remarkable efficacy in modulating macrophage polarization. In this work, we comprehensively summarize the therapeutic potential of diverse natural products, aiming to provide a comprehensive overview.</div></div><div><h3>Methods</h3><div>A literature search was performed with the keywords “atherosclerosis” or “macrophage polarization” or “herbal medicine” or “natural extracts” or “natural compounds” or “traditional Chinese medicine” or “natural products”. Classic book-based herbal and scientific databases include PubMed, CNKI, SciFinder, Scopus, Web of Science, and Google Scholar.</div></div><div><h3>Results</h3><div>This review highlights the relationship between macrophage polarization and the progression of atherosclerotic disease and discusses the limitations and future prospects of the current clinical applications of TCM and natural products, as well as the potential for therapeutic strategies targeting macrophages.</div></div><div><h3>Conclusion</h3><div>A range of natural products, such as ginsenosides, alkaloids, polysaccharides, terpenoids, flavones and quinones, have been shown to affect the treatment of atherosclerosis by modulating macrophage polarization. This study meticulously summarizes their effective dosages both <em>in vitro</em> and <em>in vivo</em>, with the intention of providing valuable insights for further drug development.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"34 ","pages":"Article 100461"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145474417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the anticancer potential of milk thistle in hepatocellular carcinoma: A network pharmacology perspective","authors":"Tushar Mishra,&nbsp;Ravinder K. Kaundal","doi":"10.1016/j.phanu.2025.100458","DOIUrl":"10.1016/j.phanu.2025.100458","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, characterized by limited therapeutic options and poor prognosis. The multifaceted nature of HCC pathogenesis, encompassing oxidative stress, immune dysregulation, angiogenesis, and metabolic reprogramming, underscores the need for multi-targeted treatment strategies. In this study, we employed an integrative network pharmacology approach to elucidate the molecular mechanisms through which Silybum marianum (Milk Thistle) constituents, particularly silymarin, exert anti-HCC effects. A total of 208 overlapping targets between Milk Thistle phytoconstituents and HCC-related genes were identified, with silymarin emerging as the most connected compound. Topological and co-expression analyses revealed 20 hub genes, including TP53, STAT3, MYC, AKT1, ESR1, and BCL2, which regulate apoptosis, proliferation, angiogenesis, and metabolism. Functional classification of these targets showed silymarin's potential to restore apoptosis via BCL2 and Caspase-3 interaction, inhibit hypoxia-induced angiogenesis through HIF-1α disruption, suppress cell cycle progression via CCND1, and impair glycolytic metabolism by targeting AKT1. Molecular docking confirmed strong interactions of silymarin with key oncogenic proteins, suggesting plausible in vivo target engagement. GO and KEGG enrichment analyses highlighted involvement in apoptosis, cytokine signaling, oxidative stress, and immune regulation. Nonetheless, this study provides a systems-level perspective of silymarin’s polypharmacological potential, positioning it as a promising multi-targeted candidate for HCC therapy, especially in overcoming resistance associated with monotherapies.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"34 ","pages":"Article 100458"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The regulation of gut microbiota and urate lowering: A study on the mechanisms of action of probiotics and plant components","authors":"Zhihua Xing ,&nbsp;Yue Xu ,&nbsp;Wen Jiang ,&nbsp;Mingyu Gao ,&nbsp;Guanghuan Shen ,&nbsp;Yingjie Liu ,&nbsp;Na Ling ,&nbsp;Linlin Cui","doi":"10.1016/j.phanu.2025.100450","DOIUrl":"10.1016/j.phanu.2025.100450","url":null,"abstract":"<div><div>The gut microbiota system serves as a \"barometer\" of human health, with significant differences observed in the intestinal microbiome between individuals with hyperuricemia (HUA) and gout compared to those in the general population. This article comprehensively reviews the correlation between gut microbiota and HUA and uric acid-lowering substances that regulate the gut microbiota. It elucidates the mechanisms underlying the occurrence and progression of HUA associated with the gut microbiota. It summarizes the effects and mechanisms through which probiotics, plant polysaccharides, and plant small molecular compounds reduce serum uric acid by modulating the gut microbiota. It is hoped that this review will provide a theoretical basis for the development of strategies for uric acid-lowering drugs targeting the gut microbiota, serving as a reference for subsequent in-depth research.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"33 ","pages":"Article 100450"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Flavonoids and macrophage polarization: Key players in the immunomodulation of cardiometabolic syndrome and related therapies","authors":"Parisa Ahmadi ,&nbsp;Soroush Taherkhani ,&nbsp;Maryam Honardoost ,&nbsp;Atousa Janzadeh","doi":"10.1016/j.phanu.2025.100449","DOIUrl":"10.1016/j.phanu.2025.100449","url":null,"abstract":"<div><div>Cardiometabolic syndrome (CMS) is a major public health challenge characterized by obesity, insulin resistance, hypertension, and chronic inflammation, which increase the risk of type 2 diabetes (T2D) and cardiovascular disease. In this context, inflammatory M1 macrophages are pivotal, as they produce proinflammatory cytokines and contribute to oxidative stress, insulin resistance, and lipid accumulation in adipose tissue. Polyphenols with anti-inflammatory, antioxidant, and antiobesity properties alleviate CMS by promoting M2 macrophage differentiation and reprogramming M1 macrophages toward the M2 phenotype. Flavonoids inhibit inflammatory pathways such as NF-kB and activator protein-1 (AP-1); reduce the expression of proinflammatory markers such as TLR4, NOD-like receptor family pyrin domain-containing 3 (NLRP-3), and inducible nitric oxide synthase (iNOS); and enhance anti-inflammatory responses, including IL-10, Nrf-1, and peroxisome proliferator-activated receptor (PPAR) expression. They prevent foam cell formation by decreasing LPX-1, CD36, scavenger receptor-A, B1, and LOX-1 expression while increasing ABCA1 and ABCG1 levels. Flavonoids are antiobesity agents that decrease the infiltration of macrophages in adipose tissue and suppress the M1 phenotype in adipose tissue macrophages, lowering inflammation and leading to the suppression of lipogenesis and stimulation of lipolysis in adipocytes. This review highlights the importance of macrophage activation in metabolic imbalance and the potential of flavonoids in treating CMS through the induction of M2 macrophages.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"33 ","pages":"Article 100449"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144770984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}